Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplemental Table 1 - PBPK model input parameters for midazolam (MDZ)
Supplemental Table 2 - PBPK model input parameters for rifampin (RIF)
Supplemental Table 3 - PBPK model input parameters for ketoconazole (KTZ)
Supplemental Table 4 - PBPK model input parameters for dexamethasone (DEX)
Supplemental Table 5 - Observed and simulated clinical PK parameters in plasma for DEX after single and multiple dosing
Supplemental Table 6 - Observed and simulated clinical PK parameters in plasma for triazolam in the absence or presence of DEX (Villikka et al., 1998)
Supplemental Table 7 - Fold change in CYP mRNA and activity with panobinostat or positive control treatment with respect to the vehicle control
Supplemental Table 8 - Kinetic parameters for panobinostat total metabolism by recombinant human CYP2C19, CYP2D6, and CYP3A4 and scaling to total HLM oxidative CLint using enzyme abundance
Supplemental Figure 1 - The impact of panobinostat fugut on Fg and DDI magnitude with ketoconazole (KTZ)
Supplemental Figure 2 - The impact of panobinostat Qgut on Fg and DDI magnitude with ketoconazole (KTZ)
Supplemental Figure 3 - Simulated plasma concentration-time profile of DEX after 20 mg single dose (Day 1)
Supplemental Figure 4 - Simulated plasma concentration-time profile of DEX after 20 mg "multiple dose" (8 mg QD or BID on Days 2-5)
Supplemental Figure 5 - The impact of rifampin (RIF) Indmax on panobinostat DDI magnitude (AUC ratio)
Supplemental References
- Supplemental Data -